Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4976153 | 0.84 | HSP90AB1 (0.48) | MAPTHSP90AB1HRH3PTPN11 | |
| SCHEMBL4977211 | 0.83 | POLB (0.48) | MAPTHSP90AB1HSP90AA1HRH3 | |
| SCHEMBL4977801 | 0.81 | POLB (0.49) | ALDH1A1MAPTHSP90AB1HSP90AA1 | |
| SCHEMBL4980389 | 0.81 | HSP90AB1 (0.45) | HSP90AB1HSP90AA1HRH3PTPN11 | |
| SCHEMBL4978212 | 0.81 | MAPT (0.43) | ALDH1A1MAPTHSP90AB1HSP90AA1HRH3 | |
| SCHEMBL4976398 | 0.81 | HCRTR1 (0.45) | MAPTHSP90AB1HSP90AA1HRH3PTPN11 | |
| SCHEMBL4979814 | 0.81 | HSP90AB1 (0.40) | ALDH1A1MAPTHSP90AB1HSP90AA1HRH3 | |
| SCHEMBL4976359 | 0.81 | HSP90AB1 (0.52) | ALDH1A1HSP90AB1HRH3PTPN11 | |
| SCHEMBL4977942 | 0.81 | KDM4E (0.53) | ALDH1A1MAPTHSP90AB1HSP90AA1HRH3 | |
| SCHEMBL4977945 | 0.80 | HCRTR1 (0.47) | ALDH1A1MAPTHSP90AB1HSP90AA1PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | HRH3, HRH4, HRH2 | CYP2D6 931/4885ALDH1A1 1142/4885HSD17B10 4078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.